NVAX / EU delays approval of Novavax's revised COVID vaccine - FT

Novavax (NASDAQ: NVAX) stock price has been a huge disappointment among investors in the past few months. After peaking at $332 during the Covid-19 pa more_horizontal

GAITHERSBURG, Md. , Nov. 2, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ more_horizontal

Novavax said on Monday it was "encouraged" by the broad availability of its updated COVID-19 vaccine being rolled out in the U.S., days after rival Pf more_horizontal

Novavax's coronavirus vaccine is one of the few currently authorized in the U.S. However, the company's competition is fierce in a market whose size i more_horizontal

European Union (EU) regulators have delayed the decision to give approval for Novavax's variant-tailored COVID-19 vaccine, the Financial Times said on more_horizontal

Despite seemingly good news, shares of biotechnology firm Novavax (NASDAQ: NVAX ) suffered a significant decline. Earlier Friday morning, management a more_horizontal

Novavax said on Friday its updated COVID-19 vaccine was available across pharmacies in the United States. more_horizontal

Owing to the slow uptake of Novavax's (NVAX) COVID-19 vaccine, the company is trying to develop other vaccine candidates targeting different indicatio more_horizontal